Flagship explainer
What drives Indivior Pharmaceuticals, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $210M | FY2025 |
| |
| Income before tax | $239M | FY2025 |
|
| Operating income | $262M | FY2025 |
|
| $1.2B | FY2025 |
| |
| Ending assets | $1.2B | FY2025 |
|
| Beginning assets | $1.3B | FY2024 |
|
| −$98M | FY2025 |
| |
| −$337M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001625297-25-000016
- SEC filingFiling detailsAccession 0001628280-26-012237